[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-370199-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-370199-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","ubiquitination-enzymes-in-cancer-cancer-immune-evasion-and-potential-therapeutic-opportunities","Ubiquitination Enzymes in Cancer, Cancer Immune Evasion, and Potential Therapeutic Opportunities","","Ubiquitination is the second most abundant posttranslational protein modification after phosphorylation, with the ubiquitin–proteasome system (UPS) underpinning essential processes including cell cycle control, DNA damage repair, and apoptosis. Mutations in ubiquitination pathway genes are linked to the development and dissemination of multiple cancers because UPS components can act as oncogenic factors or tumor suppressors. The review explains the “ubiquitin code” in cancer biology and immune evasion and summarizes recent progress targeting UPS members using inhibitors and PROTACs across preclinical and clinical studies.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/ubiquitination-enzymes-in-cancer-cancer-immune-evasion-and-potential-therapeutic-opportunities/370199/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/ubiquitination-enzymes-in-cancer-cancer-immune-evasion-and-potential-therapeutic-opportunities/370199.png","ImageObject",300,407,{"name":42,"@type":43},"Lucas Martin","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-11-01","2026-09-23",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",9,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What roles do the ubiquitin–proteasome system (UPS) play in cells?","Question",{"text":63,"@type":64},"The UPS maintains essential processes such as cell cycle control, DNA damage repair, and apoptosis. It is also involved in immune response and responses to oxidative stress.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"How is ubiquitination carried out through E1, E2, and E3 enzymes?",{"text":68,"@type":64},"Ubiquitin is activated by E1, transferred to E2 through a transthiolation reaction, and then attached to the substrate by E3. E3 provides substrate specificity and catalyzes formation of the covalent isopeptide bond.",{"name":70,"@type":61,"acceptedAnswer":71},"How does monoubiquitination differ from other ubiquitination outcomes?",{"text":72,"@type":64},"Monoubiquitination is described as primarily non-degradative. It can enhance protein–protein interactions, change protein activity, and control subcellular localization.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},370199,1790215773,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,111,115,119,122,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":108,"show_sort_weight":109,"slug":110},7,"Healthcare",40,"healthcare",{"id":112,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":113,"slug":114},8,30,"research-report",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":116,"show_sort_weight":117,"slug":118},"Religion & Spirituality",20,"religion-spirituality",{"id":117,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":117,"slug":121},"World Cup","world-cup",{"id":123,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":123,"slug":125},10,"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":112,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":139,"language":140,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":12,"update_tm":144,"read_time":145,"preview_page_count":33,"preview_urls":146},8796095360427,"https://ap-avatar.wpscdn.com/davatar_994ba38a5ba835b3df7d355c54d3ed8d","Review  \nUbiquitination Enzymes in Cancer, Cancer Immune Evasion, and Potential Therapeutic Opportunities  \nAiman B. Awan 1,†, Maryiam Jama Ali Osman 1,2,† and Omar M. Khan 1, *  \nAcademic Editor: Bernat Crosas  \nReceived: 11 November 2024  \nRevised: 16 December 2024  \nAccepted: 24 December 2024  \nPublished: 7 January 2025  \nCitation: Awan, A.B.; Osman, M.J.A.; Khan, O.M. Ubiquitination Enzymes in Cancer, Cancer Immune Evasion, and Potential Therapeutic Opportunities. Cells 2025, 14, 69 . [https://doi.org/10.3390/](https://doi.org/10.3390/)[ ](https://doi.org/10.3390/)cells14020069  \nCorrection Statement: This article has been republished with a minor change. The change does not affect the scientific content of the article and further details are available within the backmatter of the website version of this article.  \nCopyright: © 2025 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license ([https://creativecommons.org/](https://creativecommons.org/)[ ](https://creativecommons.org/)[licenses/by/4.0/](licenses/by/4.0/)) .  \n1 College of Health and Life Sciences, Hamad Bin Khalifa University, Doha P.O. Box 34110, Qatar; [aibu38539@hbku.edu.qa](aibu38539@hbku.edu.qa) (A.B.A.); [maos34113@hbku.edu.qa](maos34113@hbku.edu.qa) (M.J.A.O.)  \n2 Research Branch, Sidra Medicine, Doha P.O. Box 34110, Qatar  \n* Correspondence: [okhan@hbku.edu.qa](okhan@hbku.edu.qa)[ ](okhan@hbku.edu.qa)† These authors contributed equally to this work.  \nAbstract: Ubiquitination is cells’ second most abundant posttranslational protein modification after phosphorylation. The ubiquitin–proteasome system (UPS) is critical in maintaining essential life processes such as cell cycle control, DNA damage repair, and apoptosis. Mutations in ubiquitination pathway genes are strongly linked to the development and spread of multiple cancers since several of the UPS family members possess oncogenic or tumor suppressor activities. This comprehensive review delves into understanding the ubiquitin code, shedding light on its role in cancer cell biology and immune evasion. Furthermore, we highlighted recent advances in the field for targeting the UPS pathway members for effective therapeutic intervention against human cancers. We also discussed the recent update on small-molecule inhibitors and PROTACs and their progress in preclinical and clinical trials.  \nKeywords: ubiquitination; cell cycle; E3 ligases; oncogenes; tumor suppressor; PROTACs; cancer; immune evasion  \n1. Introduction  \nUbiquitination is a reversible covalent protein modification first discovered ~26 years ago [1,2] . It is an addition of an ~8.5 kDa ubiquitin protein on another protein that typically occurs on the acceptor lysine of the substrate protein. Although non-lysine and nonproteinaceous ubiquitination is also possible and is discussed in detail elsewhere [3] . Largely, ubiquitination serves as a signal for proteasome-mediated protein degradation [4] . However, non-degradative ubiquitination also occurs and is responsible for controlling diverse cellular functions [4] .  \nUbiquitination is one of the most abundant and evolutionarily conserved posttranslational protein modifications, so much so that all proteins undergo at least one ubiquitination event during their lifecycle [4] . It is a multi-step process carried out in a sequential manner by ubiquitin-activating (E1), ubiquitin-conjugating (E2), and ubiquitin ligase enzymes (E3)—collectively regarded as the ubiquitin–proteasome system (UPS) (Figure 1) . The UPS is a tightly regulated system that breaks down intracellular proteins. It controls various cellular processes, including cell cycle control, DNA damage repair, signal transduction, immune response, and response to oxidative stress.  \nFigure 1. The ubiquitination cascade. A ubiquitin molecule is first charged by the E1 enzyme at the expense of an ATP molecule. T","cbCaigKSAg8jorLt","https://ap.wps.com/l/cbCaigKSAg8jorLt","pdf",1160503,35,"English","# 1. Introduction\n# 2. Types of Ubiquitination","[{\"question\":\"What roles do the ubiquitin–proteasome system (UPS) play in cells?\",\"answer\":\"The UPS maintains essential processes such as cell cycle control, DNA damage repair, and apoptosis. It is also involved in immune response and responses to oxidative stress.\"},{\"question\":\"How is ubiquitination carried out through E1, E2, and E3 enzymes?\",\"answer\":\"Ubiquitin is activated by E1, transferred to E2 through a transthiolation reaction, and then attached to the substrate by E3. E3 provides substrate specificity and catalyzes formation of the covalent isopeptide bond.\"},{\"question\":\"How does monoubiquitination differ from other ubiquitination outcomes?\",\"answer\":\"Monoubiquitination is described as primarily non-degradative. It can enhance protein–protein interactions, change protein activity, and control subcellular localization.\"}]","Ubiquitination Enzymes in Cancer, Cancer Immune Evasion, and Potential Therapeutic Opportunities | PDF",1790187309,88,[147,151,155,159],{"page_no":22,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/bc097601862edd53d29f19cc61cfd6d2.webp",983,1390,{"page_no":26,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/6ac04080ad71b635b6945abc7b4e7156.webp",982,1388,{"page_no":30,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/17aa929c8dcd7b801e47b639bbd653ae.webp",981,1387,{"page_no":33,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/b43a0abd2468a0d88db51ccc35be6d1a.webp",980,1385]